chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccination site spot; Arm freezes up in movement; It kills her. Cannot reach the tip of shoulder; Missed second dose (6 weeks since first dose); Missed second dose (6 weeks since first dose); Soreness around injection site; Numbness all over her left arm up to her wrist; Can't sleep at night on her left side; feeling something on the joint, like she can feel it moving"; Couldn't lift her arm; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numbness all over her left arm up to her wrist), INSOMNIA (Can't sleep at night on her left side), MUSCULOSKELETAL DISCOMFORT (feeling something on the joint, like she can feel it moving"), LIMB DISCOMFORT (Couldn't lift her arm) and VACCINATION SITE DISCOLOURATION (Vaccination site spot) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M2DA) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced HYPOAESTHESIA (Numbness all over her left arm up to her wrist), INSOMNIA (Can't sleep at night on her left side), MUSCULOSKELETAL DISCOMFORT (feeling something on the joint, like she can feel it moving"), LIMB DISCOMFORT (Couldn't lift her arm) and VACCINATION SITE PAIN (Soreness around injection site). On 07-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose (6 weeks since first dose)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed second dose (6 weeks since first dose)). On an unknown date, the patient experienced VACCINATION SITE DISCOLOURATION (Vaccination site spot), HYPOKINESIA (Arm freezes up in movement) and PAIN (It kills her. Cannot reach the tip of shoulder). On 27-Feb-2021, LIMB DISCOMFORT (Couldn't lift her arm) had resolved. On 07-Apr-2021, PRODUCT DOSE OMISSION ISSUE (Missed second dose (6 weeks since first dose)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed second dose (6 weeks since first dose)) had resolved. At the time of the report, HYPOAESTHESIA (Numbness all over her left arm up to her wrist), INSOMNIA (Can't sleep at night on her left side), MUSCULOSKELETAL DISCOMFORT (feeling something on the joint, like she can feel it moving"), VACCINATION SITE DISCOLOURATION (Vaccination site spot), HYPOKINESIA (Arm freezes up in movement), PAIN (It kills her. Cannot reach the tip of shoulder) and VACCINATION SITE PAIN (Soreness around injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not reported. Treatment details not provided. Patient agreed to be contacted for a follow up.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jun-2021: Follow up information received on 27-Jun-2021 and included Details about the adverse event and outcome of the events were updated.
Feel nauseous; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Feel nauseous) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NAUSEA (Feel nauseous). At the time of the report, NAUSEA (Feel nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications reported. No treatment information was provided.
This case was reported by a physician to a sales rep and described the occurrence of lymph node swelling in a subject of unspecified age and gender who was vaccinated with diphtheria and tetanus toxoids acellular pertussis vaccine adsorbed (Infanrix) for prophylaxis. The physician reported to the sales representative that several subjects experienced adverse events following the administration of Infanrix, however, a specific number of subjects was not provided. On an unspecified date before 01Mar06, the subject a dose of Infanrix (dose number and lot number not provided). At an unspecified time after vaccination with Infanrix, on an unspecified date on or before 01Mar06, the subject experienced lymph node swelling, fever and pain. The outcome of the events was not reported.
Below the injection site- redness, slightly raised, itching.  taking benadryl, cool compress, benadryl cream topically.
It greatly reduced my nasal polyps which I have suffered for years; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as single dose for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious), outcome "unknown", described as "It greatly reduced my nasal polyps which I have suffered for years".  No follow-up attempts are possible. No further information is expected.
Patient's mother reported that she took daughter to a pediatrician who dismissed symptoms. Mother then took child to another Dr. Dr diagnosed HSP vasculitis and encouraged mother to call hospital and report reaction.
Initial report was received 22 April 2010 from a press article. A 22-year-old male college student had received a meningococcal vaccination before entering college (manufacturer, lot number, route, site and date of administration not reported), and an unspecified amount of time later on 13 April 2010, the patient reported feeling ill. He was taken to the emergency room by his friends at approximately 5:30pm and within hours (also reported as before 11:30pm), he died from meningococcal disease/bacterial meningitis. According to the report, test results (not specified) were pending. No additional information was provided at the time of the report. Documents held by sender: None.
The vials expired on 13-May-2022 and placed in refrigerator on 17-May-2022 and administered on 19-May-2022; Dose administered post the expiration or beyond use date; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT STORAGE ERROR (The vials expired on 13-May-2022 and placed in refrigerator on 17-May-2022 and administered on 19-May-2022) and EXPIRED PRODUCT ADMINISTERED (Dose administered post the expiration or beyond use date) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003K21-2A, 011F21A, 045A21A and 031M20A) for COVID-19 prophylaxis.     The patient's past medical history included Cardiac pacemaker insertion. Concurrent medical conditions included Blood pressure high.   On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 02-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On 19-May-2022 at 9:06 AM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On 19-May-2022 at 9:06 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered post the expiration or beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vials expired on 13-May-2022 and placed in refrigerator on 17-May-2022 and administered on 19-May-2022). At the time of the report, PRODUCT STORAGE ERROR (The vials expired on 13-May-2022 and placed in refrigerator on 17-May-2022 and administered on 19-May-2022) and EXPIRED PRODUCT ADMINISTERED (Dose administered post the expiration or beyond use date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered EXPIRED PRODUCT ADMINISTERED (Dose administered post the expiration or beyond use date) to be not related. No further causality assessment was provided for PRODUCT STORAGE ERROR (The vials expired on 13-May-2022 and placed in refrigerator on 17-May-2022 and administered on 19-May-2022).    No concomitant medications was reported.  The vaccines expired on 13-May-2022 and administered on 19-May-2022. The vials were placed in refrigerator on 17-May-2022.  The patient had no known allergies. It was unknown if the patient was diagnosed or tested positive for COVID-19. Also unknown if the patient had acute illnesses at the time of vaccination and up to one month before and unknown if prescriptions, over-the-counter medications, dietary supplements or herbal remedies were taken at time of vaccination and/or at the time of the adverse event. It was also unknown if the patient had experienced a similar event in the past.  No treatment medications was reported.
The next day, I flet lethargic all day; I got severe chills; headache; Dose received: 3; I couldn't sleep that night at all; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 20Oct2021 09:30 (Lot number: FE3590) at the age of 66 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "allergies: Penicillin" (unspecified if ongoing); "low tolerance to Narcotics or pain meds" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EL9264, Location of injection: Arm Left, Vaccine Administration Time: 03:30 PM), administration date: 13Feb2021, when the patient was 65 years old, for covid-19 immunization; Bnt162b2 (Dose Number: 2, Batch/Lot No: EN6204, Location of injection: Arm Left, Vaccine Administration Time: 01:00 PM), administration date: 06Mar2021, when the patient was 65 years old, for COVID-19 Immunization. The following information was reported: CHILLS (non-serious) with onset 20Oct2021 23:30, outcome "recovered" (2021), described as "I got severe chills"; HEADACHE (non-serious) with onset 20Oct2021 23:30, outcome "recovered" (2021), described as "headache"; INSOMNIA (non-serious) with onset 20Oct2021, outcome "recovered" (2021), described as "I couldn't sleep that night at all"; LETHARGY (non-serious) with onset 21Oct2021, outcome "recovered" (2021), described as "The next day, I felt lethargic all day"; IMMUNISATION (non-serious) with onset 20Oct2021 09:30, outcome "unknown", described as "Dose received: 3". Therapeutic measures were not taken as a result of chills, headache, insomnia, lethargy, immunisation.  Additional Information : No other vaccine in four weeks. No Other medications in two weeks. No covid prior vaccination. Patient was not tested post vaccination for covid. Facility type Vaccine was Pharmacy or Drug Store. After vaccination next day felt lethargic all day. Patient did not have the side effects on the last 2 doses. Follow-up attempts are completed. No further information is expected.
Pt was exposed to chickenpox through his brother who on 11/02/1998 was vaccinated with one dose of varicella virus vaccine live. On 05/09/1999 the pt experienced a rash consistent with chickenpox. The rash consisted of 5-6 areas with grouped vesicles on an erythematous base.
total time out of range is 48 hours with a maximum temperature of 67.6F reported with no reported adverse event.; Initial information received on 28-Feb-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a patient with unknown demographics whos vaccine total time out of range is 48 hours with a maximum temperature of 67.6f reported with no reported adverse event. while receiving vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE with unknown dose,lot number not reported via unknown route in unknown administration site for immunization.  On an unknown date the patient had a non-serious total time out of range is 48 hours with a maximum temperature of 67.6f reported with no reported adverse event (product temperature excursion issue) (unknown latency) following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (total time out of range is 48 hours with a maximum temperature of 67.6F reported with no reported adverse event.).  At time of reporting, the outcome was Unknown for the event total time out of range is 48 hours with a maximum temperature of 67.6f reported with no reported adverse event..
Hives on abdomen, chest, back, lets, feet, arms and soles of feet. Benadryl 25mg at 9:00pm and Benadryl 25mg at 11:00;m. Today still has a few but not itching.
The heaviest and most painful menstrual period of my life.; The heaviest and most painful menstrual period of my life.; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 12:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), colestipol (MANUFACTURER UNKNOWN) and loratadine (CLARITIN); all for unknown indications from an unknown date and unknown if ongoing. On 21Apr2021 at 12:00, the patient experienced heaviest and most painful menstrual period in life. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events heaviest and most painful menstrual period of in life was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Patient received both HPV 9 and meningococcal (MCV4P) immunizations in the same left deltoid. Later the same evening he developed redness over his entire deltoid along with warmth at the site, soreness, fever at home, headache.  He was given cool compress, ibuprofen.  No other treatment, took several days to resolve.
ended up in hospital with pneumonia; Initial information received on 01-Oct-2021 regarding an unsolicited valid serious case received from a consumer via social media.  This case involves an unknown age female patient who ended up in hospital with pneumonia (pneumonia) after receiving INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed serious ended up in hospital with pneumonia (pneumonia) (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant. The patient was hospitalized for this event.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the event outcome reported as unknown for the event.; Sender's Comments: This poorly documented social media case concerns a female patient (unknown age) who experienced pneumonia after vaccination with INFLUENZA VACCINE (produced by unknown manufacturer). The time to onset was unknown. Further information regarding medical history, concurrent condition during vaccination, previous vaccination and tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
First of all the site doing the administration was dirty and no gloves were used.  Non sanitary storage of vaccines and bandages.    Approximately 10 hrs post injection I had a 101.1 fever, chills, sweats, headache, unbearable joint pain, headache, and nausea.  Symptoms are ongoing still now.  Fever has broke but other symptoms remain although seem to be lessening 36 hrs later
caller have a heart disease; This spontaneous case was reported by a patient and describes the occurrence of CARDIAC DISORDER (caller have a heart disease) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced CARDIAC DISORDER (caller have a heart disease). At the time of the report, CARDIAC DISORDER (caller have a heart disease) outcome was unknown.            The case was created as Invalid as there was no Moderna product involved as a suspect.  No concomitant medications were reported.  The patient received vaccines, one from Pfizer vaccine, one from Moderna vaccine and another one from manual precautionary created vaccine.  The patient reported to have a heart disease.  No treatment medications were reported.
did not receive her second shot; nervous and "anxious" because of side reaction; red circle spread till elbow area; swollen injection site; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (did not receive her second shot), NERVOUSNESS (nervous and "anxious" because of side reaction), MYALGIA (sore arm), VACCINATION SITE ERYTHEMA (red circle spread till elbow area) and VACCINATION SITE SWELLING (swollen injection site) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced MYALGIA (sore arm). On 27-Jan-2021, the patient experienced NERVOUSNESS (nervous and "anxious" because of side reaction), VACCINATION SITE ERYTHEMA (red circle spread till elbow area) and VACCINATION SITE SWELLING (swollen injection site). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (did not receive her second shot). The patient was treated with IBUPROFEN at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 09-Feb-2021, NERVOUSNESS (nervous and "anxious" because of side reaction), MYALGIA (sore arm), VACCINATION SITE ERYTHEMA (red circle spread till elbow area) and VACCINATION SITE SWELLING (swollen injection site) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (did not receive her second shot) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient treated symptoms by warm compress.
Patient says the Pneumovax made her arm swell and become rock hard, she got a headache that lasted for 2 weeks, and subsequently had 2 mini strokes. She did not have any high blood pressure issues or pre-existing conditions before
Pt recv vax on 3/24/99; on 3/25/99 pt exp pinpoint, bumpy rash; tx=Motrin
Morsilliform rash, arthralgia, malaise - Information has been received from a physician concerning a 54 year old female who on 14 feb 2001 was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live second generation lot 635917/0825K.  On 26 Feb 2001 the patient experienced a mealses like rash on her trunk arms, thighs, and face that was described as red blotchy spots.  The patient also reported joint pain and general malaise.  It was indicated that  the patient did not have a fever.  Unspecified medical attention was sought.  No further information was provided.  Additonal information has been requested.
Extreme anxiety and derealization late that Friday afternoon. It disrupted my sleep - lots more sleep panic, tinnitus, noises in my ears, ear pain, facial pain, headache, low mood, low energy, brain fog. I started sleeping longer and later for some reason. Before the vaccine I would usually wake up at 10:30- 11AM. After, I started sleeping until 12-1 PM. The acute symptoms except for sleep continued for 2 months. Sleep is still an issue with delayed sleep schedule. Currently my body needs to sleep until 2 pm most days
SUSPECTED COVID-19 INFECTION; Runny nose; This spontaneous report received from a patient via a company representative concerned a 30 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: moderate to severe adult crohn's disease. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch and lot numbers. Non-company suspect drugs included: adalimumab (solution for injection in pre-filled pen, subcutaneous, batch number was not reported) dose was not reported, 1 time every 2 weeks, from 12-APR-2021 for moderate to severe adult crohn's disease. No concomitant medications were reported.  On 27-AUG-2021, the patient experienced runny nose. On 30-AUG-2021, the patient experienced suspected covid-19 infection. Laboratory data included: COVID-19 virus test (NR: not provided) Positive. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from runny nose, and the outcome of suspected covid-19 infection was not reported. This report was non-serious.